Latest filings (excl ownership)
8-K
Other Events
22 Apr 24
8-K
Regulation FD Disclosure
9 Apr 24
8-K
Departure of Directors or Certain Officers
1 Apr 24
8-K
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
28 Mar 24
8-K
Termination of a Material Definitive Agreement
14 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
8-K
Entry into a Material Definitive Agreement
5 Mar 24
DEFA14A
Additional proxy soliciting materials
14 Feb 24
DEF 14A
Definitive proxy
14 Feb 24
PRE 14A
Preliminary proxy
31 Jan 24
8-K/A
Independent Auditor’s Report
23 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
S-8
Registration of securities for employees
12 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-A12G
Registration of securities
8 Dec 23
D/A
$60.25 mm in other securities, sold $60.25 mm, 2 investors
4 Dec 23
EFFECT
Notice of effectiveness
4 Dec 23
D
$60.25 mm in other securities, sold $60.25 mm, 2 investors
1 Dec 23
S-3/A
Shelf registration (amended)
1 Dec 23
CORRESP
Correspondence with SEC
1 Dec 23
8-K
Departure of Directors or Certain Officers
27 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
DEFA14A
Additional proxy soliciting materials
13 Nov 23
8-K
Entry into a Material Definitive Agreement
13 Nov 23
8-K
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
31 Oct 23
CORRESP
Correspondence with SEC
30 Oct 23
UPLOAD
Letter from SEC
30 Oct 23
S-3
Shelf registration
25 Oct 23
8-K
Departure of Directors or Certain Officers
25 Sep 23
8-K
Other Events
13 Sep 23
S-8
Registration of securities for employees
17 Aug 23
10-Q
2023 Q2
Quarterly report
17 Aug 23
8-K
Results of Operations and Financial Condition
17 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
DEFA14A
Additional proxy soliciting materials
13 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
Latest ownership filings
3
Emily English
19 Apr 24
SC 13D/A
SPRINGER TIMOTHY A
12 Apr 24
4
Michael Singer
10 Apr 24
4
Murat Kalayoglu
10 Apr 24
4
TIMOTHY A SPRINGER
10 Apr 24
4
Christopher M Jewell
10 Apr 24
4
Milos Miljkovic
10 Apr 24
4
Metin Kurtoglu
10 Apr 24
SC 13D/A
Kalayoglu Murat
10 Apr 24
SC 13D/A
Singer Michael
10 Apr 24
4
Elizabeth Hoge
10 Apr 24
SC 13D/A
SPRINGER TIMOTHY A
28 Mar 24
4
TIMOTHY A SPRINGER
28 Mar 24
4
TIMOTHY A SPRINGER
26 Mar 24
4
TIMOTHY A SPRINGER
20 Mar 24
4
TIMOTHY A SPRINGER
18 Mar 24
SC 13G/A
FMR LLC
11 Mar 24
SC 13G/A
MANGROVE PARTNERS IM, LLC
14 Feb 24
SC 13G/A
Artal International S.C.A.
9 Feb 24
SC 13G
FMR LLC
9 Feb 24
4
Michael Singer
4 Jan 24
4
Blaine Davis
4 Jan 24
4
Christopher M Jewell
4 Jan 24
4
Carsten Brunn
4 Jan 24
4
Aymeric Sallin
4 Jan 24
4
TIMOTHY C BARABE
4 Jan 24
4
TIMOTHY A SPRINGER
4 Jan 24
4
Milos Miljkovic
4 Jan 24
4
Nishan M DeSilva
4 Jan 24
4
CARRIE SMITH COX
4 Jan 24
4
PATRICK J ZENNER
4 Jan 24
4
Murat Kalayoglu
4 Jan 24
4
Metin Kurtoglu
4 Jan 24
SC 13D
Singer Michael
22 Nov 23
SC 13D
Kalayoglu Murat
22 Nov 23
3
Elizabeth Hoge
17 Nov 23
SC 13D/A
SPRINGER TIMOTHY A
17 Nov 23
4
Blaine Davis
15 Nov 23
4
Carsten Brunn
15 Nov 23
4
TIMOTHY A SPRINGER
15 Nov 23